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The aim – to investigate the changes of protease-antiprotease system in patients with chronic obstructive pulmonary disease (COPD) in combination with arterial hypertension (AH) while progression of chronic heart failure (HF).
Materials and methods. The study involved 80 patients with
AH and COPD with II–III degrees of airway obstruction (54 men
and 26 women, mean age 64.02±1.54 years). The first group
consisted of 42 patients with AH and COPD and NYHA class
II HF; the second group consisted of 39 patients with AH and
COPD and NYHA class III HF. The comparison groups consisted
of 25 individuals with AH and NYHA class II–III HF (16 men and 9
women, mean age 61.38±2.21 years) and 20 healthy individuals.
The concentration of serum matrix metalloprotease 9 (MMP-9)
was determined by ELISA, serum α2-macroglobulin content was
determined by immunoturbidimetric method.
Results. Patients with AH and COPD demonstrated
increased serum levels of MMP-9 on 75 % as compared to the
control group (p<0.05), while α2-macroglobulin levels showed
only a tendency to increase on 11.3 % (p>0.05). In comparison
with AH patients with AH and COPD showed increased serum
MMP-9 on 21.3 % (p<0.05) and a tendency of α2-macroglobulin
increase on 7,1 % (p>0,05), indicating a significant activation
of proteolysis and lack of its inhibition in combined pathology.
While HF progression from NYHA class II HF to NYHA class
III HF patients with AH and COPD showed the decrease of
α2-macroglobulin from 2.64±0.16 to 2.24±0.13 g/l, indicating a weakening of antiprotease mechanisms while progression of HF.
Statistically significant difference between serum levels of MMP-9 in patients with AH and COPD while progression of HF was not found – 13.34±1.25 ng/ml in NYHA class II HF and 11.72±0.92
ng/ml in NYHA class III HF (p>0.05). The observed tendency of
MMP-9 decrease was possibly due to its exhaustion. The study
of the relationships between α2-macroglobulin, MMP-9 and
parameters of echocardiographic parameters of the left ventricle
in patients with AH and COPD showed correlations between
α2-macroglobulin and end systolic diameter (r=-0.32; p<0.05),
end diastolic diameter (r=-0.30; p<0.05), end diastolic volume
(r=-0.30; p<0.05), left ventricular posterior wall thickness (r=0,84;
p<0,05) interventricular septal wall thickness (r=0.77; p<0.05);
MMP-9 and left ventricular posterior wall thickness (r=0.63;
p<0.05), interventricular septal wall thickness (r=0.63; p<0.05),
end systolic diameter (r=-0.30; p<0.05), end diastolic diameter
(r=-0.30; p<0.05) and end systolic volume (r=-0.30; p<0.05).
Positive correlations of α2-macroglobulin with left ventricular wall
thickening are in agreement with Padmasekar M., Nandigama R.
and Wartenberg M., who also reported about the involvement of
α2-macroglobulin in the development of myocardial hypertrophy.
Conclusions. The progression of HF in patients with AH and COPD is accompanied by the decrease of the proteolysis inhibitor α2-macroglobulin along with high activity of connective tissue degradation processes as observed by increased MMP-9. The observed protease-antiprotease imbalance in patients with AH and COPD causes the changes in extracellular matrix proteins metabolism, resulting in myocardial remodeling, that underlies the pathogenesis of HF.

